Can Anastrozole Cause Liver Enzyme Elevations?
Yes, anastrozole can cause elevations in hepatic transaminases, though this is an uncommon adverse effect that is explicitly recognized in the FDA drug label. 1
FDA-Recognized Hepatotoxicity
The FDA label for anastrozole clearly documents hepatobiliary adverse events in post-marketing surveillance, including:
- Increases in alkaline phosphatase
- Elevations in alanine aminotransferase (ALT)
- Elevations in aspartate aminotransferase (AST)
- Increases in gamma-GT and bilirubin
- Frank hepatitis 1
In pediatric studies, increased ALT and AST were specifically noted as adverse reactions possibly related to anastrozole treatment 1. This establishes that transaminase elevation is a recognized, though infrequent, complication of anastrozole therapy.
Clinical Evidence and Patterns
Comparative Hepatotoxicity Profile
Anastrozole actually demonstrates a more favorable hepatic safety profile compared to tamoxifen. A prospective randomized study of 353 postmenopausal women showed that anastrozole had significantly lower cumulative incidence of fatty liver disease (14.6% vs 41.1%, P < 0.0001) compared to tamoxifen, though abnormal liver function tests occurred at similar rates in both groups (24.6% vs 24.7%) 2. This suggests that while transaminase elevations can occur with anastrozole, the overall hepatic impact may be less severe than alternative hormonal therapies.
Rare but Serious Hepatotoxicity
Case reports document more severe hepatotoxic reactions:
- Drug-induced liver injury (DILI) with jaundice and significant transaminase elevation occurring as early as 4 days after initiation 3
- Delayed hepatotoxicity presenting after 4 years of therapy with significantly elevated liver enzymes (scored as "possible" DILI on Roussel Uclaf Causality Assessment) 4
- Autoimmune hepatitis as an extremely rare complication, presenting with elevated transaminases, autoantibodies, and requiring immunomodulatory treatment 5
Clinical Implications and Monitoring
When to Suspect Anastrozole-Related Hepatotoxicity
Consider anastrozole as the culprit when patients develop:
- Unexplained elevation of ALT/AST (typically 2-5 times upper limit of normal initially)
- Jaundice or icterus
- Right upper quadrant abdominal pain
- General malaise with yellowing of skin or sclera 1
Important Caveats
Drug interactions matter: Concomitant medications that inhibit hepatobiliary transport (telmisartan, metformin, amlodipine) may potentiate hepatotoxicity risk 3
Latency period varies: Hepatotoxicity can occur within days or after years of therapy, so maintain vigilance throughout treatment 3, 4
Autoimmune hepatitis requires specific workup: If transaminases remain elevated after drug discontinuation, check antinuclear antibodies, anti-smooth muscle antibodies, and immunoglobulins; consider liver biopsy 5
Reversibility: Liver enzymes typically normalize after anastrozole discontinuation, supporting causality 3, 4
Monitoring Recommendations
The FDA label states that anastrozole can cause inflammation of the liver and changes in liver function tests, and that doctors may check for this 1. Stop anastrozole immediately if patients develop signs of liver injury (jaundice, right upper quadrant pain, general malaise) and perform comprehensive hepatic workup to exclude other causes 1.
While transaminase elevation with anastrozole is uncommon, it is a recognized adverse effect that requires clinical awareness, particularly given the drug's widespread use in breast cancer treatment and the potential for serious hepatotoxicity in rare cases.